•
Jun 30, 2023
ClearPoint Neuro Q2 2023 Earnings Report
Reported record revenue and biologics & drug delivery growth.
Key Takeaways
ClearPoint Neuro reported a record quarterly revenue of $6.0 million, a 14% year-over-year increase, driven primarily by the growth in biologics and drug delivery services.
Reported record quarterly revenue of $6.0 million, a 14% year-over-year increase.
Increased biologics and drug delivery revenue to $3.4 million, a 40% year-over-year increase.
Installed multiple new PRISM laser therapy units and continued the limited market release in the U.S.
Cash and cash equivalents totaled $26.5 million as of June 30, 2023.
ClearPoint Neuro
ClearPoint Neuro
ClearPoint Neuro Revenue by Segment
Forward Guidance
The Company reaffirms its full year 2023 revenue outlook of between $25.0 and $27.0 million.
Positive Outlook
- Accelerating revenue growth
- Adding meaningful strategic and milestone-based biologics and drug delivery agreements
- Expanding our PRISM limited market release to multiple new centers
- Executing as many as five FDA submissions directly or through partnerships for new products
- Completing the qualification of our new manufacturing clean room facility in Carlsbad, California and producing sellable product
Revenue & Expenses
Visualization of income flow from segment revenue to net income